SPORTS
May 22, 2012 | By Bill Shaikin
PHOENIX — Andre Ethier said Tuesday he does not plan to impose a deadline on negotiations on the contract extension that could keep him out of free agency. Dodgers General Manager Ned Colletti has said he would like to re-sign Ethier and has discussed the idea with Dodgers President Stan Kasten , who took office three weeks ago. Ethier said Tuesday he and his agent have not received a formal contract proposal from the Dodgers. Ethier also said he did not anticipate a point where free agency could be so close that he would put any contract talks on hold before he could test the market.
BUSINESS
October 30, 2011 | Ken Bensinger, Los Angeles Times
First of three parts Tiffany Lee wanted a car. She was weary of the two-hour bus ride to her job at a UCLA Health System clinic. She hated having to ask friends to drive her 7-year-old son to his asthma treatments. But as a single mother with three children, bad credit and a $27,000-a-year salary, she couldn't find a bank or dealership willing to give her a loan. Then a friend steered her to Repossess Auto Sales in Hawthorne. Another buyer might have balked at the deal she was offered.
NATIONAL
May 19, 2012 | By Mitchell Landsberg, Los Angeles Times
CINCINNATI - The Rev. Chris Beard is a theological conservative, make no mistake about it. He believes the Bible is the word of God. He believes the Holy Spirit speaks to him directly. He believes, as an article of faith, that abortion and same-sex marriage are wrong. Still, when a group of religious leaders in Ohio held two days of meetings in Cincinnati recently to talk about economic and racial justice, issues usually associated with the political left, there was Beard, a fourth-generation Pentecostal preacher with a disarming smile, a shaved head and a set of convictions that knock holes in the stereotypes about white evangelical Protestants.
SPORTS
September 14, 2011 | By Sam Farmer
Brian Price, once a wrecking ball on UCLA's defensive line, has beaten long odds to return to the NFL after two off-season surgeries aimed at keeping his hamstrings attached to his pelvis, rather than breaking loose and coiling down the backs of his thighs. For Price, who will start at defensive tackle Sunday for the Tampa Bay Buccaneers, his excruciating recovery was a 10-step process. Meaning just two months ago, he could run only 10 steps. "You have these doubts in your head at times," said Price, a second-round pick of the Buccaneers in 2010 who, because of his congenitally malformed pelvis, spent the last half of his rookie season on injured reserve.
CALIFORNIA | LOCAL
July 27, 2011 | By Ari Bloomekatz, Abby Sewell and Kate Mather, Los Angeles Times
Bob Brickman spent months fighting a ticket he got last fall from a red-light traffic camera at Wilshire and Sepulveda boulevards in West Los Angeles. The 61-year-old from Playa Vista eventually decided to give up the fight and fork over the $476 fine. Now he's regretting paying every penny. City officials this week spotlighted a surprising revelation involving red-light camera tickets: Authorities cannot force violators who simply don't respond to pay them. For a variety of reasons, including the way the law was written, Los Angeles officials say the fines for ticketed motorists are essentially "voluntary" and there are virtually no tangible consequences for those who refuse to pay. The disclosure comes as the city is considering whether to drop the controversial photo enforcement program, with the City Council scheduled to vote on the matter Wednesday.
HEALTH
March 22, 2012 | By Melissa Healy, Los Angeles Times
Watching Alzheimer's disease steal away the memory, talents and very selves of its victims is hard enough for the people who love them. Now, a new pill formulated by a respected pharmaceutical company and approved by the Food and Drug Administration will do little to help most patients and will bring misery to some, say two medical investigators. The drug, Aricept 23 mg, is no more effective on the whole than the disappointing ones already on the market - but is more likely to cause gastrointestinal problems, wrote Drs. Steven Woloshin and Lisa Schwartz of Dartmouth Medical College in an article published Thursday in the medical journal BMJ. The new formulation was devised to serve commercial objectives, they say, and was approved despite a poor showing in company-sponsored tests.